DOUTHWAITE, HANNAH,WALDRON-LYNCH, MAEVE,BRADLEY, DENISE,ENG-WONG, JENNIFER
申请号：
CA3040913
公开号：
CA3040913A1
申请日:
2017.11.02
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Methods for the treatment of HER2-positive breast cancer are provided by neoadjuvant administration of pertuzumab and trastuzumab in combination with anthracycline-based chemotherapy. In particular, the methods concerns the treatment patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer by neoadjuvant administration of pertuzumab and trastuzumab following anthracycline-based chemotherapy, wherein the combined administration of pertuzumab and trastuzumab increases pathological complete response (pCR) relative to administration of trastuzumab as a single agent, without significant increase in adverse events, such as cardiac toxicity, relative to neoadjuvant anthracycline-based chemotherapy.
